30S Stock Overview
Saniona AB (publ), a biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Denmark.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Saniona AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.13 |
| 52 Week High | kr0.96 |
| 52 Week Low | kr0.13 |
| Beta | 1 |
| 1 Month Change | -10.54% |
| 3 Month Change | -22.38% |
| 1 Year Change | -80.40% |
| 3 Year Change | -94.65% |
| 5 Year Change | -94.73% |
| Change since IPO | -95.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 30S | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.5% | -5.1% | -2.0% |
| 1Y | -80.4% | -21.1% | -0.3% |
Return vs Industry: 30S underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: 30S underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| 30S volatility | |
|---|---|
| 30S Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 30S's share price has been volatile over the past 3 months.
Volatility Over Time: 30S's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 23 | Thomas Feldthus | www.saniona.com |
Saniona AB (publ), a biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Denmark. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity.
Saniona AB (publ) Fundamentals Summary
| 30S fundamental statistics | |
|---|---|
| Market cap | €17.26m |
| Earnings (TTM) | -€8.26m |
| Revenue (TTM) | €1.45m |
11.9x
P/S Ratio-2.1x
P/E RatioIs 30S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 30S income statement (TTM) | |
|---|---|
| Revenue | kr16.84m |
| Cost of Revenue | kr5.06m |
| Gross Profit | kr11.78m |
| Other Expenses | kr107.59m |
| Earnings | -kr95.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 69.96% |
| Net Profit Margin | -568.94% |
| Debt/Equity Ratio | -297.3% |
How did 30S perform over the long term?
See historical performance and comparison